Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
|Articles|April 1, 2002
Infliximab finds utility in management of pyoderma gangrenosum
New Orleans - The experiences of an expanding series of patients indicate infliximab (Remicade) is a valuable therapy for the management of pyoderma gangrenosum (PG), Marketa Limova, M.D., said at the annual meeting of the American Academy of Dermatology.
Advertisement
Advertisement
Related to this article
Clinicians discuss how type 2 inflammation informs treatment decisions across AD, prurigo nodularis, CSU, and bullous pemphigoid.
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.
Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.
A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.
Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
2
Dermatology Times Monthly FDA and Pipeline Review: October 2026
3
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
4
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
5